Definium Reports Positive Results for DT120

Definium Therapeutics announced positive trial data and outlined a commercial plan for its lead psychiatric drug candidate, DT120.

Updated on Nov. 16, 2026 in Biotech

Isometric editorial illustration of plain glass vials and a steel pipette rack on a clean laboratory bench in oxblood, teal, and slate tones, suggesting drug development progress.
Definium Therapeutics reported positive trial results for its lead psychiatric drug DT120 on Monday and said it plans to file a New Drug Application in the first half of 2027. AI Illustration. Upload story photo >

Definium Therapeutics announced positive clinical trial results for DT120, its lead psychiatric drug candidate, during its third-quarter 2026 earnings call. The company ended the quarter with $1.05 billion in cash, cash equivalents, and investments.

Why it matters

The results move DT120 closer to a potential regulatory filing, with the company planning a New Drug Application in the first half of 2027. The company also holds breakthrough therapy designations and expedited review status for the drug.

Definium completed three Phase 3 trials for DT120 across generalized anxiety disorder and major depressive disorder, and ended the third quarter with $1.05 billion in cash, equivalents, and investments. The source material does not detail the specific efficacy results from these trials, and the company's Phase 2a autism study for DT402 was stopped after five participants.

The players

Definium Therapeutics

Definium Therapeutics is a publicly traded biotechnology company developing treatments for psychiatric conditions, with DT120 as its lead candidate.

The details

Management stopped enrollment in a Phase 2a study of DT402 in adults with autism spectrum disorder after five participants because it detected clear early efficacy signals across core symptoms. The company announced these updates on its third-quarter 2026 financial results conference call on November 9, 2026.

Timeline

  1. November 9, 2026: Definium holds its third-quarter 2026 conference call and announces trial results.

  2. First half of 2027: Planned submission of a New Drug Application for DT120.

  3. 2030: Company expects its cash balance to fund commercial preparations for DT120 through this year.

Regulatory Pathway

DT120 holds dual breakthrough therapy designations from the FDA, a status created to speed development and review of drugs for serious conditions. The company's planned 2027 New Drug Application places the candidate within that expedited framework for psychiatric treatments.

If approved, DT120 would add a new option for adults living with generalized anxiety disorder or major depressive disorder. The timeline runs through a 2027 filing, so patients would not have access to the drug before that review concludes.

The takeaway

Definium's progress shows how breakthrough designations can compress the path from late-stage trials to a possible filing. Readers tracking psychiatric treatments should watch whether the company meets its first-half 2027 submission target.

What happens next

Definium Therapeutics plans to submit a New Drug Application for DT120 in the first half of 2027.

Further reading

Explore more biotech developments covering drug trials and regulatory milestones.

Source note: This article includes information reported by The Motley Fool.